Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993018 · ClinicalTrials.gov registry record · Phase 2
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00993018 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 77 participants.
The verdict
NCT00993018, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the analgesic efficacy, safety and tolerability of multiple doses of JNJ-42160443 when administered as a single, subcutaneous injection every 28 days to patients with diabetic painful neuropathy (a disease condition in diabetic patients that affects all peripheral nerves including pain fibers, motor neurons and the autonomic nervous system).
Interventions
- DRUG Placebo
- DRUG JNJ-42160443 (1 mg)
- DRUG JNJ-42160443 (3 mg)
- DRUG JNJ-42160443 (10 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993018
The ClinicalTrials.gov registry entry for NCT00993018 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00993018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00993018 about?
NCT00993018 is a clinical study titled "A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy". The purpose of this study is to evaluate the analgesic efficacy, safety and tolerability of multiple doses of JNJ-42160443 when administered as a single, subcutaneous injection every 28 days to patients with diabetic painful neuropathy (a disease condition in diabetic patients that affects all perip...
What is the current status of trial NCT00993018?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2009-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00993018?
The interventions under investigation include: Placebo (DRUG), JNJ-42160443 (1 mg) (DRUG), JNJ-42160443 (3 mg) (DRUG), JNJ-42160443 (10 mg) (DRUG).
Who is sponsoring clinical trial NCT00993018?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.